January 11, 2013

$PVCT @ #JPM13: Immunotherapeutic Potential

The conversation with Big Pharma has changed considerably after SSO in March 2012. Big Pharma and Big Biotech eyes are on Moffitt's pre-clinical and clinical work. Discussion of immunotherapeutic compound potential at the conference was prominent.

Provectus News today listed the attention the company's January 8 press release about the Moffitt human trial has garnered thus far:
Sign up for Provectus News here.

No comments:

Post a Comment